| Home | E-Submission | Sitemap | Contact Us |  
Clin Exp Otorhinolaryngol Search


Principles of Transparency and Best Practice > About > Principles of Transparency and Best Practice

As an open access journal, CEO will follow the Principles of Transparency and Best Practice in Scholarly Publishing (https://doaj.org/bestpractice) developed by Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishers Association (OASPA), and the World Association of Medical Editors (WAME).

1. Website

The URL of official journal web site is https://www.e-ceo.org.

The CEO team endeavors to make a good website. CEO website demonstrates that care has been taken to ensure high ethical and professional standards. It does not contain any misleading information, including any attempt to mimic another journal/publisher’s site.

2. Name of Journal

The official journal title is Clinical and Experimental Otorhinolaryngology (herein “CEO”), the abbreviation of ISO is Clin Exp Otorhinolaryngol. Prior to launching CEO thorough checks are made to ensure no journal of a similar name already exists.

3. Peer Review Process

The CEO has on online submission and peer review system at http://mc04.manuscriptcentral.com/e-ceo.

CEO reviews all manuscripts received. A manuscript is first reviewed for its format and adherence to the aims and scope of the journal. If the manuscript does not fit the aims and scope of the Journal or does not adhere to the Instructions for authors, it may be returned to the author immediately after receipt and without a review. Before reviewing, all submitted manuscripts are inspected by Similarity Check powered by iThenticate (https://www.crossref.org/services/similarity-check/), a plagiarism-screening tool.

The manuscripts are sent to two or more most relevant investigators for review of the contents. The editor selects peer referees by recommendation of the Editorial Board members or from the specialist database owned by the Editorial Board. The peer review process takes usually four to 8 weeks after the manuscript submission.

4. Ownership and Management

This journal is owned by the publisher, the Korean Society of Otorhinolaryngology-Head and Neck Surgery (https://www.korl.or.kr).

5/6. Governing Body / Editorial Team and Contact Information

The governing body is the journal's editorial board. The full names and affiliations of the journal’s editors and members of journal management team are displayed on the About (Editorial Board & Journal Management Team) tab of journal homepage, and the contact information for the Editor and editorial office is on the About (Contact Us) tab.

7. Copyright and Licensing

Copyright to all published materials is owned by the Korean Society of Otorhinolaryngology-Head and Neck Surgery. All authors should agree to the copyright transfer during the submission process.

CEO is an open access journal. Articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To use the tables or figures of CEO in other journals, books or media for scholarly, educational purposes, the process of permission request to the publisher of CEO is not necessary. All contents of the journal are available immediately upon publication without embargo period.

8. Author Fees

Article processing charges are required for publication in CEO. These cover some of the costs of publication as well as open access online editions in the journal website or in the PubMed Central. Invoice will be sent to the corresponding author when the submitted article is finally accepted. The charge is USD 300 per article. They are displayed on the Author Information (Article Processing Charge) tab of journal homepage.

9. Process for Identification of and Dealing with Allegations of Research Misconduct

The editorial board of CEO have carefully examined all submitted manuscripts whether these are abided by the ethical guidelines of the ICMJE and COPE. The published articles have involved the statements of conflict of interest, institutional review board, informed consent, and human/animal rights.

When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the COPE (http://publicationethics.org/resources/flowcharts). The editorial board of CEO will discuss the suspected cases and reach a decision. CEO will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.

10. Publication Ethics

CEO follows the Guideline on Good Publication of COPE (https://publicationethics.org), Recommendations of International Committee of Medical Journal Editors (http://www.icmje.org/recommendations), and Good Publication Practice Guidelines for Medical Journals of Korean Association of Medical Journal Editors (http://kamje.or.kr).

Our publication ethics are displayed on the Editorial Policy (Publication Ethics) tab of journal homepage.

11. Publishing Schedule

CEO is published 4 times (the last day of March, June, September, December) a year. The e-pub versions of all articles have been promptly seen after the acceptance in the journal homepage and the PubMed Central.

12. Access

CEO is an open access journal. A free full-text service both in the XML and PDF formats is available immediately upon publication without embargo period.

13. Archiving

Full text of CEO has been archived in PubMed Central (PMC)/Europe PMC (http://www.ncbi.nlm.nih.gov/pmc/journals/880/) and National Library of Korea (http://www.nl.go.kr) from the 1st volume, 2008. According to the deposit policy (self-archiving policy) of Sherpa/Romeo (http://www.sherpa.ac.uk), authors cannot archive pre-print (i.e., pre-refereeing), but they can archive post-print (i.e., final draft post-refereeing). Authors can archive publisher's version/PDF. CEO provides the electronic backup and preservation of access to the journal content in the event the journal is no longer published by archiving in PubMed Central and National Library of Korea.

14. Revenues sources

Revenue sources of journal are from the support of publisher (The Korean Society of Otorhinolaryngology-Head and Neck Surgery), Korea Government’s support, author fees, and advertising rates.

15. Advertising

CEO accepts advertisements. The policy of advertising is displayed on the Editorial Policy (Advertising Policy) tab of journal homepage.

16. Direct Marketing

Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.

Email Alert
Author's Index
Best Reviewers
Journal Impact Factor 2.9
SCImago Journal & Country Rank
  • Level of Contamination of Positive Airway Pressure Devices Used in Obstructive Sleep Apnea Clin Exp Otorhinolaryngol. 2024;17(2):160-167.

  • Korean Society of Otorhinolaryngology-Head and Neck Surgery
    Editorial Office
    Korean Society of Otorhinolaryngology-Head and Neck Surgery
    103-307 Park Tower officetel, Yongsan-dong 5-ga, Yongsan-gu, Seoul 04385, Korea
    TEL: +82-2-711-9091   FAX: +82-2-3487-6603   E-mail: editor.eceo@gmail.com
    Copyright © Korean Society of Otorhinolaryngology-Head and Neck Surgery.                 Developed in M2PI
    Close layer
    prev next